{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:21:02Z","timestamp":1790709662078,"version":"4.1.0"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:title>Graphical Abstract<\/jats:title><jats:p><jats:fig><jats:caption><jats:p>The nanoparticles with different size, shape and structure for drug delivery against <jats:italic>Leishmania donovani<\/jats:italic>.<\/jats:p><\/jats:caption><\/jats:fig><\/jats:p>","DOI":"10.3389\/fbioe.2022.1016925","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:50:40Z","timestamp":1671007840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis\u2014An updated review"],"prefix":"10.3389","volume":"10","author":[{"given":"Prakash","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salil","family":"Khajuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod Kumar","family":"Rajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravichandiran","family":"Velayutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jphotobiol.2016.05.003","article-title":"Isatis tinctoria mediated synthesis of amphotericin B-bound silver nanoparticles with enhanced photoinduced antileishmanial activity: A novel green approach","volume":"161","author":"Ahmad","year":"2016","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2147\/ijn.s23883","article-title":"Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light","volume":"6","author":"Allahverdiyev","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e00048","DOI":"10.1128\/cmr.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.idc.2018.10.004","article-title":"Cutaneous leishmaniasis","volume":"33","author":"Aronson","year":"2019","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12879-015-0928-6","article-title":"Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME\u212210, a new liposomal amphotericin B","volume":"15","author":"Asad","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1517\/17425247.2013.838216","article-title":"Polymeric colloidal particulate systems: Intelligent tools for intracellular targeting of antileishmanial cargos","volume":"10","author":"Asthana","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s11095-015-1651-0","article-title":"Overexpressed macrophage mannose receptor targeted nanocapsules-mediated cargo delivery approach for eradication of resident parasite: In vitro and in vivo studies","volume":"32","author":"Asthana","year":"2015","journal-title":"Pharm. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2217\/nnm.14.182","article-title":"Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: In vitro and in vivo studies","volume":"10","author":"Asthana","year":"2015","journal-title":"Nanomedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejpb.2014.11.019","article-title":"Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid\u2013polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B","volume":"89","author":"Asthana","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1128\/aac.01984-12","article-title":"Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules","volume":"57","author":"Asthana","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0005-2736(02)00581-3","article-title":"Comparative molecular dynamics simulations of amphotericin B\u2013cholesterol\/ergosterol membrane channels","volume":"1567","author":"Baginski","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"Balasegaram","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jac\/38.1.145","article-title":"Drug delivery system: Targeting of pentamidines to specific sites using sugar grafted liposomes","volume":"38","author":"Banerjee","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1566524043360186","article-title":"Macrophage specific drug delivery in experimental leishmaniasis","volume":"4","author":"Basu","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0743","article-title":"Amphotericin B formulations and other drugs for visceral leishmaniasis","volume":"92","author":"Berman","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9872095","article-title":"Current visceral leishmaniasis research: A research review to inspire future study","volume":"2018","author":"Bi","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijwd.2019.01.002","article-title":"Cutaneous leishmaniasis: A neglected disfiguring disease for women","volume":"5","author":"Bilgic-Temel","year":"2019","journal-title":"Int. J. Women's. Dermatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/hv.26796","article-title":"Polymeric nanoparticles: Potent vectors for vaccine delivery targeting cancer and infectious diseases","volume":"10","author":"Bolhassani","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-food-030713-092354","article-title":"Nanodelivery of bioactive components for food applications: Types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles","volume":"5","author":"Borel","year":"2014","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/jof6040321","article-title":"Amphotericin B and other polyenes\u2014Discovery, clinical use, mode of action and drug resistance","volume":"6","author":"Carolus","year":"2020","journal-title":"J. Fungi (Basel)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnano.2021.624564","article-title":"Synergism of zinc oxide quantum dots with antifungal drugs: Potential approach for combination therapy against drug resistant Candida albicans","volume":"3","author":"Chand","year":"2021","journal-title":"Front. Nanotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro1748z","article-title":"Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s11095-016-1985-2","article-title":"Bioinspired calcium phosphate nanoparticles featuring as efficient carrier and prompter for macrophage intervention in experimental leishmaniasis","volume":"33","author":"Chaurasia","year":"2016","journal-title":"Pharm. Res."},{"key":"B27","volume-title":"Immunoadjuvant chemotherapy of visceral","author":"Chitosan","year":"2013"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1046\/j.0022-202x.2001.00038.x","article-title":"Leishmaniasis as an emerging infection","author":"Choi","year":"2001","journal-title":"J. Investigative Dermatology Symposium Proc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40089-017-0208-0","article-title":"Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int. Nano Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/cmr.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1590\/s0036-46652006000300007","article-title":"Visceral leishmaniasis in Brazil: Revisiting paradigms of epidemiology and control","volume":"48","author":"Dantas-Torres","year":"2006","journal-title":"Rev. Inst. Med. Trop. S. Paulo"},{"key":"B32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/tcrm.s3581","article-title":"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India","volume":"5","author":"Das","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"B33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1529-8019.2009.01272.x","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"22","author":"David","year":"2009","journal-title":"Dermatol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40257-015-0114-z","article-title":"Cutaneous leishmaniasis: Recent developments in diagnosis and management","volume":"16","author":"de Vries","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"Aaps J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0035-9203(01)90223-8","article-title":"The increase in risk factors for leishmaniasis worldwide","volume":"95","author":"Desjeux","year":"2001","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0004087","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study","volume":"9","author":"Diro","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.exppara.2018.07.017","article-title":"In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion","volume":"192","author":"do Vale Morais","year":"2018","journal-title":"Exp. Parasitol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.18433\/j3r30t","article-title":"Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations","volume":"13","author":"Doroud","year":"2010","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12639-021-01379-w","article-title":"Efficacy and safety of single-dose liposomal amphotericin B in patients with visceral leishmaniasis in Bangladesh: A real-life experience","volume":"45","author":"Ekram","year":"2021","journal-title":"J. Parasit. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/pharmaceutics12010029","article-title":"Lipid systems for the delivery of amphotericin B in antifungal therapy","volume":"12","author":"Faustino","year":"2020","journal-title":"Pharmaceutics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijpddr.2018.03.005","article-title":"Synergistic combination of alkylphosphocholines with peptaibols in targeting Leishmania infantum in vitro","volume":"8","author":"Fragiadaki","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"B44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1365-4632.2010.04558.x","article-title":"Post\u2010kala\u2010azar dermal leishmaniasis\u2013an overview","volume":"49","author":"Ganguly","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1515\/jtim-2015-0002","article-title":"Leishmaniasis revisited: Currentaspects on epidemiology, diagnosisand treatment","volume":"3","author":"Georgiadou","year":"2015","journal-title":"J. Transl. Int. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1128\/cmr.12.4.501","article-title":"Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.19-0931","article-title":"Combination therapy against Indian visceral leishmaniasis with liposomal amphotericin B (fungisome(TM)) and short-course miltefosine in comparison to miltefosine monotherapy","volume":"103","author":"Goswami","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4269\/ajtmh.14-0657","article-title":"Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome\u2122)","volume":"94","author":"Goswami","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0169-409x(01)00104-1","article-title":"Amphotericin B colloidal dispersion: An improved antifungal therapy","volume":"47","author":"Guo","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1111\/bph.13149","article-title":"Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: An approach for non\u2010toxic chemotherapy","volume":"172","author":"Gupta","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11095-014-1571-4","article-title":"Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: Applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis","volume":"32","author":"Gupta","year":"2015","journal-title":"Pharm. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1021\/mp400603t","article-title":"Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation","volume":"11","author":"Gupta","year":"2014","journal-title":"Mol. Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/10611860701453836","article-title":"Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis","volume":"15","author":"Gupta","year":"2007","journal-title":"J. Drug Target."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e16445","DOI":"10.7759\/cureus.16445","article-title":"Conventional amphotericin B associated nephrotoxicity in patients with hematologic malignancies","volume":"13","author":"Gursoy","year":"2021","journal-title":"Cureus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cncr.23311","article-title":"Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"B56","doi-asserted-by":"crossref","first-page":"571242","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: Current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol. Biol. Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: Current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol. Biol. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1615\/critrevtherdrugcarriersyst.2013007419","article-title":"A pharmacokinetic overview of nanotechnology-based drug delivery systems: An ADME-oriented approach","volume":"30","author":"Hamidi","year":"2013","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"B59","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"B60","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2014.09.014","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"73","author":"Handler","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e00306","DOI":"10.1128\/aac.00306-21","article-title":"In vitro and in vivo antifungal activity of AmBisome compared to conventional amphotericin B and fluconazole against Candida auris","volume":"65","author":"Herrada","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijpharm.2011.01.044","article-title":"Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a distigmasterylhemisuccinoyl-glycero-phosphocholine liposome-intercalated amphotericin B","volume":"408","author":"Iman","year":"2011","journal-title":"Int. J. Pharm. X."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s11095-009-9841-2","article-title":"Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone\u00ae","volume":"26","author":"Italia","year":"2009","journal-title":"Pharm. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s12010-014-1084-y","article-title":"Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles","volume":"174","author":"Jain","year":"2014","journal-title":"Appl. Biochem. Biotechnol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12951-021-00853-0","article-title":"Nanotechnology based solutions for anti-leishmanial impediments: A detailed insight","volume":"19","author":"Jamshaid","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/695382","article-title":"Antimony resistance in Leishmania, focusing on experimental research","volume":"2011","author":"Jeddi","year":"2011","journal-title":"J. Trop. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/nano8121028","article-title":"Surface charge-dependent cellular uptake of polystyrene nanoparticles","volume":"8","author":"Jeon","year":"2018","journal-title":"Nanomater. (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00249-014-0983-8","article-title":"Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments","volume":"43","author":"Kami\u0144ski","year":"2014","journal-title":"Eur. Biophys. J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/aac.01499-13","article-title":"Hepatotoxicity of pentavalent antimonial drug: Possible role of residual Sb (III) and protective effect of ascorbic acid","volume":"58","author":"Kato","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B70","doi-asserted-by":"crossref","first-page":"726328","DOI":"10.1155\/2014\/726328","article-title":"Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania","volume":"2014","author":"Kaur","year":"2014","journal-title":"J. Parasitol. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-6-244","article-title":"Combination therapy using Pentostam and Praziquantel improves lesion healing and parasite resolution in BALB\/c mice co-infected with Leishmania major and Schistosoma mansoni","volume":"6","author":"Khayeka\u2013Wandabwa","year":"2013","journal-title":"Parasit. Vectors"},{"key":"B72","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbamem.2018.11.006","article-title":"The pore-forming action of polyenes: From model membranes to living organisms","volume":"1861","author":"Kristanc","year":"2019","journal-title":"Biochimica Biophysica Acta - Biomembr."},{"key":"B73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12977-015-0204-2","article-title":"The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells","volume":"12","author":"Kumar","year":"2015","journal-title":"Retrovirology (Auckl)."},{"key":"B74","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13346-018-00602-1","article-title":"Macrophage ghost entrapped amphotericin B: A novel delivery strategy towards experimental visceral leishmaniasis","volume":"9","author":"Kumar","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.2147\/ijn.s196421","article-title":"<p&gt;Synthesis, characterization, and mechanistic studies of a gold nanoparticle\u2013amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity&lt;\/p&gt;","volume":"14","author":"Kumar","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.msec.2017.02.145","article-title":"Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis","volume":"75","author":"Kumar","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"B77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3109\/10717544.2014.891271","article-title":"Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani","volume":"22","author":"Kumar","year":"2015","journal-title":"Drug Deliv. (Lond)."},{"key":"B78","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3109\/02652048.2011.559283","article-title":"In vitro evaluation of the antioxidant activity of liposomal flavonols by the HRP\u2013H2O2\u2013luminol system","volume":"28","author":"Landi-Librandi","year":"2011","journal-title":"J. Microencapsul."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1128\/aac.01586-09","article-title":"Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis","volume":"54","author":"Lestner","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B80","first-page":"147","volume-title":"Leishmaniasis\u2013HIV coinfection: Current challenges","author":"Lindoso","year":"2016"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.addr.2008.09.001","article-title":"Polysaccharides-based nanoparticles as drug delivery systems","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.idc.2004.11.005","article-title":"Cutaneous leishmaniasis in the returning traveler","volume":"19","author":"Magill","year":"2005","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B83","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3144\/expresspolymlett.2016.84","article-title":"Polymeric nanoparticles: Recent development in synthesis and application","volume":"10","author":"Mallakpour","year":"2016","journal-title":"Express Polym. Lett."},{"key":"B84","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12951-018-0413-7","article-title":"The impact of nanoparticle-driven lysosomal alkalinization on cellular functionality","volume":"16","author":"Manshian","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"10667","DOI":"10.1021\/ja051597r","article-title":"Mycosamine orientation of amphotericin B controlling interaction with ergosterol: Sterol-dependent activity of conformation-restricted derivatives with an amino-carbonyl bridge","volume":"127","author":"Matsumori","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.1371\/journal.pntd.0000818","article-title":"Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent","volume":"4","author":"Meheus","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B87","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.actatropica.2017.05.022","article-title":"Atypical presentations of cutaneous leishmaniasis: A systematic review","volume":"172","author":"Meireles","year":"2017","journal-title":"Acta Trop."},{"key":"B88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1472-8206.2003.00168.x","article-title":"Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients","volume":"17","author":"Minodier","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B89","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/tmi.12996","article-title":"Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis","volume":"22","author":"Mistro","year":"2017","journal-title":"Trop. Med. Int. Health"},{"key":"B90","first-page":"185","article-title":"Effectiveness of paromomycin on cutaneous leishmaniasis in Iran: A systematic review and meta-analysis","volume":"44","author":"Moradzadeh","year":"2019","journal-title":"Iran. J. Med. Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pt.2013.12.004","article-title":"Post kala-azar dermal leishmaniasis: An unresolved mystery","volume":"30","author":"Mukhopadhyay","year":"2014","journal-title":"Trends Parasitol."},{"key":"B92","first-page":"114","article-title":"Therapeutic response and safety of the topical, sequential use of antiseptic, keratolytic, and pentamidine creams (3-PACK) on Leishmania (Viannia) braziliensis-infected mice","author":"Mu\u00f1oz","year":"2019","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"B93","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/10611860903115290","article-title":"In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis","volume":"18","author":"Nahar","year":"2010","journal-title":"J. Drug Target."},{"key":"B94","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijantimicag.2008.10.013","article-title":"N-(2-hydroxypropyl) methacrylamide\u2013amphotericin B (HPMA\u2013AmB) copolymer conjugates as antileishmanial agents","volume":"33","author":"Nicoletti","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B95","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm. X."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/ma11071167","article-title":"Antileishmanial activity of amphotericin B-loaded-PLGA nanoparticles: An overview","volume":"11","author":"Palma","year":"2018","journal-title":"Materials"},{"key":"B97","article-title":"Current treatment of leishmaniasis: A review","volume":"1","author":"Palumbo","year":"2009","journal-title":"Am. J. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1c00859","DOI":"10.1021\/acsbiomaterials.1c00859","article-title":"Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles","author":"Parvez","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-69276-5","article-title":"Modified solid lipid nanoparticles encapsulated with amphotericin B and paromomycin: An effective oral combination against experimental murine visceral leishmaniasis","volume":"10","author":"Parvez","year":"2020","journal-title":"Sci. Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/j.1365-3156.2009.02329.x","article-title":"Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: Report of four cases","volume":"14","author":"Patel","year":"2009","journal-title":"Trop. Med. Int. Health"},{"key":"B101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: An update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2217\/nnm-2021-0161","article-title":"7, 8-dihydroxyflavone-functionalized gold nanoparticles target the arginase enzyme of Leishmania donovani","volume":"16","author":"Prasanna","year":"2021","journal-title":"Nanomedicine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1128\/aac.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e0005635","DOI":"10.1371\/journal.pntd.0005635","article-title":"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"11","author":"Rahman","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/pharmaceutics14050989","article-title":"Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes","volume":"14","author":"Ramos","year":"2022","journal-title":"Pharmaceutics"},{"key":"B107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/08982104.2011.575381","article-title":"Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis","volume":"21","author":"Rathore","year":"2011","journal-title":"J. Liposome Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1128\/aac.00628-13","article-title":"Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis","volume":"57","author":"Ravis","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fcimb.2019.00229","article-title":"Miltefosine-lopinavir combination therapy against leishmania infantum infection: In vitro and in vivo approaches","author":"Rebello","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.2147\/ijn.s68966","article-title":"An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis","volume":"9","author":"Ribeiro","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B112","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/viru.2.6.17839","article-title":"Muco-cutaneous leishmaniasis in the new world: The ultimate subversion","volume":"2","author":"Ronet","year":"2011","journal-title":"Virulence"},{"key":"B113","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/md.0b013e3181e9441b","article-title":"Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis","volume":"89","author":"Safdar","year":"2010","journal-title":"Medicine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-3155-2-3","article-title":"Applications of nanoparticles in biology and medicine","volume":"2","author":"Salata","year":"2004","journal-title":"J. Nanobiotechnology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"587012","DOI":"10.3389\/fmolb.2020.587012","article-title":"Nanoparticle surface functionalization: How to improve biocompatibility and cellular internalization","volume":"7","author":"Sanit\u00e0","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1061186x.2017.1387787","article-title":"A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B","volume":"26","author":"Santos","year":"2018","journal-title":"J. Drug Target."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1016\/j.ijid.2012.12.024","article-title":"Visceral leishmaniasis: Host\u2013parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host","volume":"17","author":"Saporito","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/21691401.2018.1430699","article-title":"Design of mannosylated oral amphotericin B nanoformulation: Efficacy and safety in visceral leishmaniasis","volume":"46","author":"Sarwar","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e0007616","DOI":"10.1371\/journal.pntd.0007616","article-title":"Innovations for the elimination and control of visceral leishmaniasis","volume":"13","author":"Selvapandiyan","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e0171306","DOI":"10.1371\/journal.pone.0171306","article-title":"Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B","volume":"12","author":"Shadab","year":"2017","journal-title":"PLoS ONE"},{"key":"B121","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/rrtm.s200218","article-title":"<p&gt;Lipsosomal amphotericin B: A review of its properties, function, and use for treatment of cutaneous leishmaniasis&lt;\/p&gt;","volume":"10","author":"Shirzadi","year":"2019","journal-title":"Res. Rep. Trop. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/0378-6323.148562","article-title":"Histopathological characteristics of post kala-azar dermal leishmaniasis: A series of 88 patients","volume":"81","author":"Singh","year":"2015","journal-title":"Indian J. dermatol. Venereol. Leprol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"111279","DOI":"10.1016\/j.msec.2020.111279","article-title":"Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B(12)-stearic acid conjugate","volume":"117","author":"Singh","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1016\/s1473-3099(16)30140-2","article-title":"Elimination of visceral leishmaniasis on the Indian subcontinent","volume":"16","author":"Singh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11095-017-2293-1","article-title":"Fabrication of 3-O-sn-Phosphatidyl-L-serine anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting","volume":"35","author":"Singh","year":"2018","journal-title":"Pharm. Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ijbiomac.2017.07.161","article-title":"Chitosan coated PluronicF127 micelles for effective delivery of Amphotericin B in experimental visceral leishmaniasis","volume":"105","author":"Singh","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1166\/jbn.2011.1232","article-title":"Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis","volume":"7","author":"Singodia","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4269\/ajtmh.12-0736","article-title":"Randomized, double-blinded, phase 2 trial of WR 279, 396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama","volume":"89","author":"Sosa","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e0007253","DOI":"10.1371\/journal.pntd.0007253","article-title":"Topical paromomycin for New World cutaneous leishmaniasis","volume":"13","author":"Sosa","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4269\/ajtmh.2004.71.577","article-title":"Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis","volume":"71","author":"Soto","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B131","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/cid\/ciy619","article-title":"Topical 15% paromomycin-aquaphilic for bolivian leishmania braziliensis cutaneous leishmaniasis: A randomized, placebo-controlled trial","volume":"68","author":"Soto","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4269\/ajtmh.18-0183","article-title":"Miltefosine combined with Intralesional Pentamidine for Leishmania braziliensis cutaneous leishmaniasis in Bolivia","volume":"99","author":"Soto","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B133","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","article-title":"The history of leishmaniasis","volume":"10","author":"Steverding","year":"2017","journal-title":"Parasiteand vectors"},{"key":"B134","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"B135","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777x.62886","article-title":"Liposomal amphotericin B and leishmaniasis: Dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"e3169","DOI":"10.1371\/journal.pntd.0003169","article-title":"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: A randomized, open-label study","volume":"8","author":"Sundar","year":"","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B136","first-page":"548010","article-title":"Efficacy and safety of paromomycin in treatment of post-kala-azar dermal leishmaniasis","volume":"2014","author":"Sundar","year":"","journal-title":"ISRN Parasitol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/s0031182017002116","article-title":"Chemotherapeutics of visceral leishmaniasis: Present and future developments","volume":"145","author":"Sundar","year":"2018","journal-title":"Parasitology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4269\/ajtmh.14-0259","article-title":"Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: A phase 2 study","volume":"92","author":"Sundar","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1746-1","article-title":"Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia","volume":"16","author":"Tamiru","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"0c01505","DOI":"10.1021\/acsbiomaterials.0c01505","article-title":"Enabling oral amphotericin B delivery by merging the benefits of prodrug approach and nanocarrier-mediated drug delivery","author":"Thanki","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B142","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1021\/acs.molpharmaceut.9b00662","article-title":"Improved oral bioavailability and gastrointestinal stability of amphotericin B through fatty acid conjugation approach","volume":"16","author":"Thanki","year":"2019","journal-title":"Mol. Pharm."},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: A review","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Research"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1128\/aac.01315-13","article-title":"Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis","volume":"58","author":"Trinconi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.2174\/092986712800784694","article-title":"Active drug targeting of disease by nanoparticles functionalized with ligand to folate receptor","volume":"19","author":"Tu","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/ijn.s146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"ud Din","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"B147","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s42247-021-00168-8","article-title":"Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19","volume":"4","author":"Vahedifard","year":"2021","journal-title":"emergent Mat."},{"key":"B148","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"van Griensven","year":"2012","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B149","volume-title":"Parasitic infections: A role for C-type lectins receptors","author":"V\u00e1zquez-Mendoza","year":"2013"},{"key":"B150","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/10611860802528833","article-title":"Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres","volume":"17","author":"Veerareddy","year":"2009","journal-title":"J. Drug Target."},{"key":"B151","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1166\/jbn.2011.1230","article-title":"Loading and release of amphotericin-B from biodegradable poly (lactic-co-glycolic acid) nanoparticles","volume":"7","author":"Verma","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e0208208","DOI":"10.1371\/journal.pone.0208208","article-title":"Differentiation of mucosal lesions in mucocutaneous leishmaniasis and paracoccidioidomycosis","volume":"13","author":"Vicente","year":"2018","journal-title":"PLoS ONE"},{"key":"B153","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ddg.12595","article-title":"Leishmaniasis","volume":"13","author":"Von Stebut","year":"2015","journal-title":"JDDG J. der Deutschen Dermatologischen Gesellschaft"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/s1734-1140(12)70901-5","article-title":"Nanoparticles as drug delivery systems","volume":"64","author":"Wilczewska","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1128\/aac.49.12.5092-5098.2005","article-title":"Population pharmacokinetics of amphotericin B lipid complex in neonates","volume":"49","author":"Wu\u0308rthwein","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/s41598-017-04229-z","article-title":"The effect of shape on cellular uptake of gold nanoparticles in the forms of stars, rods, and triangles","volume":"7","author":"Xie","year":"2017","journal-title":"Sci. Rep."},{"key":"B158","doi-asserted-by":"publisher","first-page":"819329","DOI":"10.3389\/fonc.2021.819329","article-title":"The applications of gold nanoparticles in the diagnosis and treatment of gastrointestinal cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"e0005877","DOI":"10.1371\/journal.pntd.0005877","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the south-east Asia region kala-azar elimination programme","volume":"11","author":"Zijlstra","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B160","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"B161","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1210\/en.2009-1082","article-title":"Minireview: Nanoparticles and the immune system","volume":"151","author":"Zolnik","year":"2010","journal-title":"Endocrinology"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.1016925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:50:58Z","timestamp":1671007858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.1016925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":161,"alternative-id":["10.3389\/fbioe.2022.1016925"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2022.1016925","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1016925"}}